Scott Gottlieb Quotes


Over the years, EpiPen's manufacturer, Mylan, made meaningful modifications to its auto-injector pen. The company maintains some important intellectual property around these revisions. Mylan rightly argues that these features differentiate its device.


Citations

Gottlieb, Scott. "The FDA's Role in the EpiPen Price Shock." Forbes, 24 Aug. 2016.

Related Quotes

This is a very important quotation in the Patent world. One of the major justifications for giving patent monopoly to an inventor is that without the patent protection people would not invest time, effort or money to invent things. However many of the great inventors have not agreed. The original Constitutional purpose in granting patents was to stimulate disclosure of technology to other inventors and educate the nation. That is why all patents are public and can be viewed by all.


Scott Gottlieb
Scott Gottlieb
  • Born: June 11, 1972
  • Nationality: American
  • Profession: Public Servant

Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.